Clara Hidden

Plasma neutrophil gelatinase-associated lipocalin and kidney graft outcome

G. Navis, D. Groothof, S. Kunutsor, 2021, Clinical kidney journal.

S. J. L. (2018). Plasma neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease: Findings from the PREVEND

Lyanne M. Kieneker, S. Seidu, R. Dullaart, 2018 .

Plasma Calprotectin Levels Associate with Suspected Metabolic-Associated Fatty Liver Disease and All-Cause Mortality in the General Population

Lyanne M. Kieneker, S. Bakker, H. van Goor, 2022, International journal of molecular sciences.

Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study.

Lyanne M. Kieneker, S. Bakker, S. Seidu, 2018, Atherosclerosis.

Plasma neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study.

Lyanne M. Kieneker, S. Bakker, S. Seidu, 2018, Clinica chimica acta; international journal of clinical chemistry.

Plasma Neutrophil Gelatinase-Associated Lipocalin Associates with New-Onset Chronic Kidney Disease in the General Population

Lyanne M. Kieneker, R. Gansevoort, H. van Goor, 2023, Biomolecules.

Plasma Calprotectin Levels Associate With New‐Onset Hypertension in the General Population: A Prospective Cohort Study

A. Abdulle, S. la Bastide-van Gemert, R. Dullaart, 2023, Journal of the American Heart Association.

A prospective study of the association between plasma calprotectin levels and new-onset chronic kidney disease in the general population

J. Hillebrands, A. Abdulle, S. la Bastide-van Gemert, 2024, Kidney International Reports.